Rumah Sakit Kanker "Dharmais" - Pusat Kanker Nasional

What Rumah Sakit Kanker "Dharmais" - Pusat Kanker Nasional does

Rumah Sakit Kanker "Dharmais" - Pusat Kanker Nasional (Dharmais Cancer Hospital - National Cancer Center) is an Indonesian healthcare institution that, based on its institutional name, operates as a specialized oncology hospital holding a national-level designation as Indonesia's cancer center. The "Pusat Kanker Nasional" component of the name implies a government-mandated role as a referral institution for cancer treatment, likely serving patients referred from across Indonesia's archipelago and functioning as a central hub for oncology service delivery, clinical training, and potentially cancer research. The institution operates under the dharmais.co.id domain.

No further operational data is available from the source material provided. There is no disclosed information on service catalog (chemotherapy, radiotherapy, surgical oncology, etc.), bed capacity, clinical technology stack, leadership team, pricing, payer mix, business model mechanics, partnerships, financials, or technology infrastructure. The website scraping attempt returned only a loader/verification placeholder, indicating no content was successfully extracted. Consequently, this description is limited to what can be directly inferred from the institutional name and domain, and any downstream investment analysis would require primary-source diligence on clinical capacity, government budget allocation, BPJS contract structure, and service-line economics.

Name

Rumah Sakit Kanker "Dharmais" - Pusat Kanker Nasional

Website

https://dharmais.co.id

Company type

Private

Headcount range

501–1,000 employees

Short description

Rumah Sakit Kanker Dharmais - Pusat Kanker Nasional is an Indonesian cancer hospital designated as a national cancer center, providing specialized oncology care and serving as a national referral institution for cancer treatment in Indonesia under the dharmais.co.id domain.

Ownership category

akta.pro rank

Product category

Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Oncology services
• Cancer treatment
• National cancer center
• Cancer hospital
• Specialized healthcare

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Core offering

Rumah Sakit Kanker "Dharmais" is Indonesia's National Cancer Center, delivering comprehensive oncology services to cancer patients nationwide. The hospital provides cancer diagnosis, medical oncology (chemotherapy), radiation oncology, surgical oncology, and palliative care services. As a designated Pusat Kanker Nasional, it functions as the top-tier referral hospital for cancer cases within Indonesia's national health system.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Diagnosis and Pathology Services Comprehensive cancer diagnostic services including histopathology, cytology, and laboratory testing for cancer detection, staging, and monitoring. Available to patients referred from regional hospitals and walk-in patients at the Jakarta facility.
• Chemotherapy Services Medical oncology services providing chemotherapy administration for various cancer types, delivered by specialized oncologists and nursing staff at the National Cancer Center facility.
• Radiotherapy Services Radiation oncology services using radiotherapy equipment to treat cancer patients, including external beam radiation therapy as part of comprehensive cancer treatment plans.
• Surgical Oncology Services Surgical oncology procedures for cancer tumor removal, biopsy, and related surgical interventions performed by specialized surgical oncologists.
• Palliative and Supportive Care Supportive and palliative care services for cancer patients focusing on pain management, symptom control, and quality of life improvement, particularly for advanced-stage patients.
• Outpatient and Inpatient Hospital Services Hospital admission and outpatient consultation services for cancer patients, providing clinical evaluation, treatment planning, and ongoing monitoring at the National Cancer Center facility.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Regional players

• Mount Elizabeth Hospital (Oncology): Singapore-based flagship private hospital with significant oncology capability and one of Southeast Asia's most important medical tourism brands. Comparable to Dharmais as a Southeast Asian oncology provider, but serving wealthier paying patients on a private, multi-specialty platform rather than a national public mandate.

Direct peers

• Peter MacCallum Cancer Centre: Australia's flagship public specialty cancer hospital with research and teaching integration. Direct peer as a publicly-funded, single-specialty comprehensive cancer center with academic and trial capabilities.
• National Cancer Center Korea: South Korea's government-funded national cancer research and treatment institute. Directly comparable to Dharmais in scale, public ownership, national designation, and combined clinical-research-training mandate.
• National Cancer Centre Singapore: Singapore's national specialty cancer center, treating the majority of public-sector oncology cases and a major regional referral destination. Comparable to Dharmais in role as a national single-specialty oncology hub, though in a higher-income setting.
• Tata Memorial Hospital: India's premier government-backed cancer specialty hospital under the Department of Atomic Energy. Highly comparable to Dharmais as a publicly-funded, single-specialty national cancer center serving a large South Asian population with a strong research mandate.
• Royal Marsden Hospital: The UK's first hospital dedicated to cancer diagnosis, treatment, research, and education, and a globally recognized specialty oncology institution. Comparable as a single-specialty cancer hospital with strong research ties and global brand recognition.
• Charité Comprehensive Cancer Center: Comprehensive Cancer Center integrated with Charité, one of Europe's largest university hospitals. Comparable as a publicly-funded, oncology-specialized entity with strong academic and translational research programs.
• Seoul National University Cancer Hospital: South Korea's leading public cancer specialty hospital affiliated with Seoul National University Hospital. Highly comparable to Dharmais as an Asian national cancer center combining tertiary oncology care with research and training.

Broad incumbents

• MD Anderson Cancer Center: World's largest cancer specialty hospital and research center, part of the University of Texas system. Comparable to Dharmais as a public, research-intensive, single-specialty cancer center, though operating at a vastly larger scale and global benchmark standard.
• Apollo Hospitals (Cancer Institute): Asia's largest private hospital chain with a dedicated cancer institute in Chennai and other locations. Comparable to Dharmais as a high-volume Asian oncology provider, but with a private, multi-specialty model that contrasts with Dharmais's public single-specialty structure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/rumah-sakit-kanker-dharmais

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rumah Sakit Kanker "Dharmais" - Pusat Kanker Nasional